Deep Longevity is ready to launch its new SaaS anti-aging platform, SenoClock, on 09-Nov-2022. The culmination of years of biogerontological research, SenoClock will host all of Deep Longevity’s patented aging clocks that may be used in clinical practice and other healthcare-adjacent industries. Aging clocks available on the platform will allow its users to receive comprehensive and actionable pace of aging reports based on various data types, such as blood tests, psychological surveys, gut flora composition, and more.
Join us online at the product launch Event for a demonstration of SenoClock’s functions and to learn more about the science behind it.
“The aging clock as a service platform, SenoClock will allow pretty much anyone in the community to efficiently calculate their biological age using a standardized set of deep aging clocks. I hope that with time, this platform will grow into a marketplace of clocks where any credible research group will be able to put their clock in a cloud to complement to the digital models developed by Deep Longevity ” Alex Zhavoronkov, the Founder and Chief Longevity Officer of Deep Longevity, informs, “Reports generated by SenoClock will lists the biomarkers that cause aging as well as recommends the solutions to help the patients achieve healthy longevity.”
Deep Longevity’s research team has been publishinged their discoveries in the field of longevity technology since 2016. Since then, this Hong Kong-based startup has established itself as a pioneer of AI applications on the service of anti-aging. The team will shate the history of the product and future research plans in the upcoming release event.
Key features of the SenoClock portal include:
100% SaaS: - Quick and secure web access;
A variety of aging clocks: - All Deep Longevity’s clocks are available from a single application ;
Instantaneous predictions -: Get age predictions and reports in seconds ;
Highly scalable: - The capacity to process up to tens of thousands of predictions within a few minutes ;
Personalized Recommendations: - Aging predictions accompanied by personalized health plans;
“The SenoClock portal offers a unique service to the providers of the longevity industry by granting access to multiple aging clocks from a single portal in the most inexpensive manner. It will allow pioneering healthcare leaders to improve patient health using our AI- driven recommendations,” explains Deepankar Nayak, the CEO of Deep Longevity.
If you want to learn more about SenoClock or interact with the research team behind the product, follow this link to register and reserve your spot. The last date of registration is 08-Nov- 2022. The main purpose of this virtual launch is to introduce the intended users of this platform and to the possibilities it opens for decision makers from clinics and hospitals, longevity physicians, insurance companies, supplements, and consumer health goods manufacturers and distributors.
Feel free to reach out to us at firstname.lastname@example.org to contact our management and research teams and gain clarity on how SenoClock platform can be used to help your customers extend their health span as well as share your ideas and concerns.
About Deep Longevity
The Company is wholly owned by Endurance Longevity (SEHK:0575.HK), whose shares are quoted on the Hong Kong Stock Exchange, develops explainable artificial intelligence systems to track the rate of aging at molecular, cellular, tissue, organ, system, physiological, and psychological levels. It is also developing systems for the emerging field of longevity medicine, which enables physicians to make better decisions about interventions that may slow down or reverse the aging processes. Deep Longevity developed the Longevity as a Service (LaaS)© solution to integrate multiple deep biomarkers of aging dubbed “deep aging clocks” to provide a universal multifactorial measure of human biological age.
Originally incubated by Insilico Medicine, Deep Longevity began its independent journey in 2020 after securing a round of funding from the most credible venture capitalists specializing in biotechnology, longevity, and artificial intelligence: ETP Ventures; the Human Longevity and Performance Impact Venture Fund; BOLD Capital Partners; Longevity Vision Fund; LongeVC; Michael Antonov, the co-founder of Oculus; and other expert AI and biotechnology investors. Deep Longevity established a research partnership with Human Longevity, Inc., one of the most prominent longevity organizations to provide a range of aging clocks to a network of advanced physicians and researchers.
Method of Research
Subject of Research